Jay R. Luly
2013
In 2013, Jay R. Luly earned a total compensation of $1.6M as President and Chief Executive Officer at Enanta Pharmaceuticals, a 114% increase compared to previous year.
Compensation breakdown
| Bonus | $235,422 |
|---|---|
| Option Awards | $960,468 |
| Salary | $448,512 |
| Other | $4,439 |
| Total | $1,648,841 |
Luly received $960.5K in option awards, accounting for 58% of the total pay in 2013.
Luly also received $235.4K in bonus, $448.5K in salary and $4.4K in other compensation.
Rankings
In 2013, Jay R. Luly's compensation ranked 4,568th out of 12,286 executives tracked by ExecPay. In other words, Luly earned more than 62.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,568 out of 12,286 | 63rd |
Division Manufacturing | 1,562 out of 4,612 | 66th |
Major group Chemicals And Allied Products | 449 out of 1,462 | 69th |
Industry group Drugs | 312 out of 1,156 | 73rd |
Industry Pharmaceutical Preparations | 251 out of 890 | 72nd |
Source: SEC filing on January 13, 2016.
Luly's colleagues
We found two more compensation records of executives who worked with Jay R. Luly at Enanta Pharmaceuticals in 2013.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019